Biotech giant Regeneron’s (REGN) performance has been pretty ho-hum in the year so far. While Eylea sales continue to be under pressure, affecting the top line, the company finally managed to post ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click here to read why REGN is a Buy.

Learn about cost, uses, and more of Eylea (aflibercept). It’s an injectable prescription drug that treats certain eye conditions.

Eylea eye injections are given by an ophthalmologist. If you have insurance, the price of your Eylea injections may be billed through your medical coverage instead of the prescription drug portion ...

Regeneron Pharmaceuticals Inc. said an extensive investigation into a rare and frightening side effect seen in clusters of patients getting its best-selling drug Eylea has been tied to syringes ...

Eylea sales have boosted the company’s top line for many years. However, Eylea’s sales have been under pressure for the past couple of years due to competition from Roche’s (RHHBY) Vabysmo.